


RESEARCH ARTICLE

Open Access



# *Pseudomonas aeruginosa* responds to exogenous polyunsaturated fatty acids (PUFAs) by modifying phospholipid composition, membrane permeability, and phenotypes associated with virulence

Lyssa Y. Baker<sup>1</sup>, Chelsea R. Hobby<sup>1</sup>, Andrew W. Siv<sup>1</sup>, William C. Bible<sup>1</sup>, Michael S. Glennon<sup>1</sup>, Derek M. Anderson<sup>2</sup>, Steven J. Symes<sup>2</sup> and David K. Giles<sup>1\*</sup> 

## Abstract

**Background:** *Pseudomonas aeruginosa*, a common opportunistic pathogen, is known to cause infections in a variety of compromised human tissues. An emerging mechanism for microbial survival is the incorporation of exogenous fatty acids to alter the cell's membrane phospholipid profile. With these findings, we show that exogenous fatty acid exposure leads to changes in bacterial membrane phospholipid structure, membrane permeability, virulence phenotypes and consequent stress responses that may influence survival and persistence of *Pseudomonas aeruginosa*.

**Results:** Thin-layer chromatography and ultra performance liquid chromatography / ESI-mass spectrometry indicated alteration of bacterial phospholipid profiles following growth in the presence of polyunsaturated fatty acids (PUFAs) (ranging in carbon length and unsaturation). The exogenously supplied fatty acids were incorporated into the major bacterial phospholipids phosphatidylethanolamine and phosphatidylglycerol. The incorporation of fatty acids increased membrane permeability as judged by both accumulation and exclusion of ethidium bromide. Individual fatty acids were identified as modifying resistance to the cyclic peptide antibiotics polymyxin B and colistin, but not the beta-lactam imipenem. Biofilm formation was increased by several PUFAs and significant fluctuations in swimming motility were observed.

**Conclusions:** Our results emphasize the relevance and complexity of exogenous fatty acids in the membrane physiology and pathobiology of a medically important pathogen. *P. aeruginosa* exhibits versatility with regard to utilization of and response to exogenous fatty acids, perhaps revealing potential strategies for prevention and control of infection.

**Keywords:** *Pseudomonas aeruginosa*, Fatty acids, Phospholipids, Antimicrobial peptides, Biofilm, Motility

\* Correspondence: [david-giles@utc.edu](mailto:david-giles@utc.edu)

<sup>1</sup>Department of Biology, Geology, and Environmental Science, The University of Tennessee at Chattanooga, Chattanooga, TN, USA

Full list of author information is available at the end of the article



## Background

The prevalent opportunistic pathogen *Pseudomonas aeruginosa* displays an array of virulence factors and antibiotic resistance mechanisms that make it a significant public health concern, particularly for cystic fibrosis patients, burn victims and nosocomial infections. The ability of *P. aeruginosa* to thrive in diverse environments can be partially explained by its tremendous metabolic capabilities, allowing utilization of numerous substrates [1, 2]. Many of these molecules have been identified to be nutritional cues, serving as signals to guide bacterial behavior (motility, biofilm, antibiotic resistance) [3–5].

An emerging concept is that some bacteria have evolved to recognize lipid molecules in a manner that affects physiology and pathogenesis [6–8]. *Vibrio* species, for example, have been shown to incorporate exogenous fatty acids into membrane phospholipids [9, 10], causing alterations in phospholipid structure and changes in biofilm formation and motility [11]. Similar findings have been found with *Acinetobacter baumannii* and *Klebsiella pneumoniae* [12, 13]. The consequences of these modifications to membrane lipids are unknown. The effects of exogenous fatty acids on bacterial growth and virulence have been demonstrated in both Gram-negative and Gram-positive bacteria. Fatty acids have influenced motility, gene expression and survival [14–18], while inhibitory action of polyunsaturated fatty acids have been documented in several pathogens [19–21].

The mechanism for fatty acid uptake and utilization, originally studied in *E. coli*, operates by a protein dependent pathway. Exogenous fatty acids are recognized by an outer membrane protein FadL which allows transport into the periplasm [22]. FadD, an inner membrane protein, intercepts the protonated long chain fatty acids and converts them into acyl-CoA thioesters (LCFA-acyl-CoA). These products of FadD have three known fates: they can be used as transcriptional regulators, metabolized by beta oxidation, or converted to phospholipids to be incorporated into the membrane [23, 24].

Several studies have begun to establish a link between fatty acid degradation and virulence in *P. aeruginosa*. Initial studies with *P. putida* and *P. fragi* established the wide range of fatty acid substrates recognized by a dual FadD system [25]. In cystic fibrosis patients, the expression of *fadD1* and *fadD2* was demonstrated during lung infection, suggesting a valuable role of lipid acquisition in vivo [26]. The same study strengthened the connection between Fad and virulence by further characterizing the *fadD* genes and demonstrating that inactivation of either or both transcripts led to deficiencies in fatty acid and phosphatidylcholine utilization, variation in both swimming and swarming motility and a decrease in in vivo fitness using a mouse lung infection model [26].

Moreover, the discovery of a long-chain fatty acid sensor, PsrA, by Kang et al. [14, 27] lends support to the idea of fatty acids as important signaling molecules that affect environmental and host survival.

Many studies have lauded the biological benefits of long-chain polyunsaturated fatty acids (PUFAs) to human development and health [28, 29]. The effects include structural roles within membranes, bioconversion into signaling molecules, and contributions in membrane-associated processes [30–32]. The contributions of PUFAs to membrane structure, protein function and gene regulation support further research in organisms displaying an expanded ability for fatty acid metabolism. In a *P. aeruginosa* lung infection mouse model, dietary supplementation with (n-3) PUFAs led to lower mortality, as well as relief from fluid accumulation and excessive mucin secretion [33, 34]. The same PUFAs were later shown to positively affect the outcome of pulmonary infection in mice by modulating pro- and anti-inflammatory cytokines [35].

The current study investigates the changes in lipid profile in *P. aeruginosa* upon exposure to polyunsaturated fatty acids (PUFAs) and seeks to identify if such membrane modifications cause virulence-associated responses. Growth in the presence of individual PUFAs dramatically altered phospholipid profiles and variably impacted membrane permeability, biofilm formation, motility and susceptibility to antimicrobial peptides. Overall, our data underscore the importance of fatty acids in the lifestyle of pathogenic bacteria.

## Methods

### Bacterial strains and growth conditions

The laboratory strain *Pseudomonas aeruginosa* PAO1 used in this study was obtained from the Colin Manoil, University of Washington, Seattle (originating from B. Iglewski, University of Rochester Medical Center) [36]. G56 minimal medium (0.4% Glucose, 0.4% casamino acids, 150 mM NaCl) served as the growth medium unless described otherwise. A concentration of 300  $\mu$ M was used for each fatty acid (Cayman Chemicals).

### Bacterial lipid extraction and thin-layer chromatography

The method of Bligh [37] and Dyer was used to extract phospholipids from 14 ml of bacterial culture. Isolated phospholipids were deposited onto Silica Gel 60 TLC plates and subsequently separated using a solvent system consisting of chloroform, methanol and acetic acid (65:25:10 v/v/v). Visualization of phospholipids was achieved by charring plates with a solution of 10% sulfuric acid in 100% ethanol followed by heating to 150 °C for approximately 1 min. Plates were scanned using a Canon CanoScan 9000F.

### Ultra performance liquid chromatography/ESI-mass spectrometry

The methodology for analysis of extracted bacterial phospholipids can be found in previous publications [12, 13]. Briefly, the extracted phospholipids were prepared as a 300 ppm (total lipid) sample. Diluent consisted of a 50:50 mixture of solvents A and B where A = 30:70 25 mM pH 6.7 ammonium acetate:methanol and B = methanol. Chromatographic separation involved gradient elution on an ACQUITY UPLC system (Waters, Milford, MA) equipped with a BEH C8 column (2.1 × 100 mm; 1.7 μm particles). Detection of analytes was achieved by quadrupole mass spectrometry following electrospray ionization in the negative mode.

### Crystal violet uptake assay

The crystal violet assay was performed as previously described [11–13]. Briefly, 7 ml cultures of *P. aeruginosa* in G56 minimal media were grown in the presence and absence of 300 μM each PUFA to logarithmic phase. Cultures were pelleted, washed and resuspended in 5 ml PBS at an OD of 0.5. Every 5 m following addition of crystal violet (5 μg/ml), 1 ml was removed, pelleted, and the supernatant was measured at OD<sub>590</sub>. Inclusion of a control (containing CV but no bacteria) allowed normalization of the data. The amount of CV detected (representing dye not taken up) was converted to percentage of uptake using Excel. Three biological replicates were performed and all standard deviations were calculated to be less than 5% (not graphed for visual clarity).

### Ethidium bromide accumulation and exclusion assays

Methodology for measurement of the ethidium bromide excluded from bacteria has been previously published [13]. Briefly, cultures of *P. aeruginosa* were grown to logarithmic phase, pelleted, and resuspended at an OD of 0.7. Every 5 m following addition of ethidium bromide (5 μg/ml), 1 ml of culture was removed, pelleted, and the supernatant was analyzed using an excitation wavelength of 530 nm and detection wavelength of 585 nm. A control sample (containing EtBr but no bacteria) allowed normalization of the data and represents the maximal fluorescence intensity (measured as 420 nm and plotted as the 'zero' time for each sample). The measurements were performed on a Varian Cary Eclipse Fluorescence Spectrophotometer with a 20-nm excitation slit width. Three biological replicates were performed. For measurement of accumulation of ethidium bromide, *P. aeruginosa* was grown in CM9 to logarithmic phase (OD<sub>600</sub> = 0.8) in the presence and absence of 300 μM each PUFA. Bacteria were pelleted, washed with PBS and resuspended in PBS at an OD<sub>600</sub> = 0.4. After addition of 20 μM of ethidium bromide, fluorescence measurements were taken every 5 m for 1 h using a

Varian Cary Eclipse Fluorescence Spectrophotometer with a 10-nm excitation slit width (excitation wavelength of 545 nm, detection wavelength of 600 nm). Two biological replicates were performed.

### Biofilm assay

Biofilm formation was measured using a previously published method by O'Toole [38]. Briefly, *P. aeruginosa* cultures were prepared in 96-well microtiter plates containing G56 minimal medium supplemented with or without each fatty acid. Planktonic cells were removed after an incubation period of 20 h at 37 °C and the plates were gently washed. Crystal violet (0.1%) was added to each well and incubated for 15 m at room temperature. The plate was washed and allowed to dry. 30% acetic acid was added, allowed to incubate for 15 m, and the solubilized crystal violet was transferred to a fresh microtiter plate and measured at OD<sub>590</sub>. Three biological replicates were performed in octuplet and statistical significance was determined using the Students t-Test (2-tailed, paired).

### Motility assays

Soft agar assays were prepared using M9 minimal medium (0.35% agar), supplemented with 300 μM of each fatty acid. Other supplements included 2 mM MgSO<sub>4</sub>, 0.2 mM CaCl<sub>2</sub>, 0.8% glucose, 0.075 mM thiamine and 0.4% casamino acids. 2 μl of inoculum (OD<sub>600</sub> = 0.1) was pipetted into the agar and the diameters were measured after 24 h of incubation at 37 °C. Two biological replicates were performed in quadruplicate.

### Antimicrobial peptide susceptibility assay

Microtiter plate assay methodology was performed as previously published [11–13]. *P. aeruginosa* was grown to logarithmic phase in G56 or CM9. Cultures were centrifuged, washed with minimal media, and resuspended at a starting OD<sub>600</sub> of 0.1 and exposed to two-fold concentrations of polymyxin B, colistin, or imipenem. Plates were incubated for 20 h at 37 °C and a Biotek Synergy microplate reader was used to read absorbance at OD<sub>600</sub>.

## Results


### PUFA exposure results in accelerated growth and altered phospholipid profiles of *Pseudomonas aeruginosa*

The effect of PUFAs on *P. aeruginosa* phospholipids was investigated by growing bacteria in the presence and absence of micromolar concentrations of each fatty acid. Minimal medium was used to exclude fatty acid contributions of complex media, as are present in nutrient rich media. Growth curves indicated that each PUFA caused modest increases in growth rate during 12 h of incubation (Additional file 1: Figure S1). Furthermore, growth of *P. aeruginosa* was possible with each PUFA when provided as

the sole carbon source (Additional file 2: Figure S2). The major phospholipids produced by *P. aeruginosa* [phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylcholine (PC) and cardiolipin (CL)] were analyzed by thin-layer chromatography (TLC) (Fig. 1). The phospholipid profiles reflect a structural shift indicative of incorporation of the longer chain, more unsaturated fatty acid. It is possible to distinguish two distinct species of the same phospholipid, as well as possible preference for the more hydrophobic species (see PE for 20:3, 20:4 and 20:5).

#### UPLC/ESI-MS analyses indicate assimilation of exogenous PUFAs into *P. aeruginosa* phospholipids

Ultra-performance liquid chromatography/electrospray ionization mass spectrometry (UPLC/ESI-MS)




**Fig. 1** Thin-layer chromatography of phospholipids extracted from *Pseudomonas aeruginosa* grown in the presence of individual polyunsaturated fatty acids. Bacteria were grown to exponential phase ( $OD \approx 0.8$ ) in G56 minimal media at 37 °C with or without 300  $\mu$ M of the indicated fatty acids (linoleic acid [18:2], alpha-linolenic acid [18:3 $\alpha$ ], gamma-linolenic acid [18:3 $\gamma$ ], dihomo-gamma-linolenic acid [20:3], arachidonic acid [20:4], eicosapentaenoic acid [20:5] and docosahexaenoic acid [22:6]) prior to Bligh and Dyer extraction of phospholipids and separation by TLC in the solvent system chloroform/methanol/acetic acid (65:25:10 v/v/v). The plate was charred and scanned to produce the final image

was employed to better define the qualitative changes observed by TLC. Bacterial lipids were extracted following growth with individual PUFAs and subjected to chromatographic separation using reversed-phase gradient elution. The samples produced chromatograms (Fig. 2) indicating structural changes to the phospholipid profile, yielding peaks dependent upon the specific fatty acid supplemented. Figure 2a shows representative total ion chromatograms (TIC) and extracted ion chromatograms (XIC) for *Pseudomonas* cultures grown in the presence of select fatty acids. Data for all fatty acids tested is provided in the Supplemental materials (Additional file 3: Figure S3). The introduction of new chromatographic peaks absent in the control are indicative of fatty acid-modified phospholipid species.

Similar to TLC, the LC-MS results showed abundant PE and PG species. Mass spectrometry confirmed that these phospholipids are composed of fatty acyl chains derived from the exogenously supplied fatty acid. Extracted ion chromatograms from exogenous fatty acid exposed samples revealed  $[M-H]^-$  ions corresponding to phospholipid species consisting of at least one acyl chain matching the supplemented fatty acid (Fig. 2b). For example, phospholipids from fatty-acid supplemented cultures had peaks corresponding to  $[M-H]^-$  ions of  $m/z$  743.5 (16:0/18:3), 769.5 (18:1/18:3), and 793.5 (16:0/22:6), which are not present in the control (Fig. 2b; see Additional file 4: Figure S4 for mass spectra). Similarly, PE species displayed modified XIC peaks at  $m/z$  712.5 (16:0/18:3), 738.5 (18:1/18:3), 762.5 (16:0/22:6), and 788.5 (18:1/22:6) (Fig. 2b). Taken together, the data supports the assimilation of exogenously supplied fatty acids into both PG and PE of *P. aeruginosa*.

#### Exogenous fatty acids alter the membrane permeability of *P. aeruginosa*

The observed alterations to membrane phospholipid structure prompted measurement of cellular membrane permeability following fatty acid exposure. As measured using a crystal violet uptake assay, the fatty acids elicited significant alterations to permeability in *P. aeruginosa* (Fig. 3). *P. aeruginosa* displayed mostly decreased membrane permeability, with the sole exception being gamma-linolenic acid. Interestingly, the omega-3 counterpart elicited the largest decrease (> 10%) in permeability. Since crystal violet is known to bind surface components (eg, sugars, proteins) of bacterial, these modest changes to permeability were further investigated by using ethidium bromide as another measure of membrane permeability. Compared to control, each fatty acid elicited lower emission intensity of ethidium bromide excluded from bacteria over the course of 20 min (Fig. 3b). Furthermore, cell-associated fluorescence was measured with or without PUFA adaptation. This accumulation assay corroborated



the exclusion assay, indicating increased fluorescence for all fatty acids except dihomo- $\gamma$ -linolenic acid (20:3) (Fig. 3c). Collectively, this data suggests that incorporation of PUFAs increases *P. aeruginosa* membrane permeability.

### Exogenous fatty acids influence antimicrobial peptide MIC in *P. aeruginosa*

Since many antimicrobials target membrane integrity, we hypothesized that phospholipid incorporation of exogenous fatty acids would alter the bacterial response to some antimicrobials. We examined the effects of fatty acids on the MIC of two cyclic peptide antibiotics polymyxin B and colistin resistance using a microtitre plate assay (Fig. 4a and b). The assays were performed following growth in the presence of 300  $\mu$ M fatty acid, with continued fatty acid availability during assay incubation. Several fatty acids (18:2, 20:4 and 20:5) led to an increase in polymyxin B MIC. Strikingly, arachidonic acid caused an 8-fold increase in MIC of polymyxin B. In another minimal medium (CM9), the increase for arachidonic acid held; however, the MIC for docosahexaenoic acid was increased 4-fold (Fig. 4d). Three fatty acids (18:3 $\gamma$ , 20:4 and 22:6) conferred two-fold protection against colistin. No significant difference was observed when the beta-lactam imipenem was used (Fig. 4c).

### Exogenous PUFAs affect swimming motility in *P. aeruginosa*


Motility represents another phenotype associated with virulence in *P. aeruginosa* infections. Small molecules (e.g., fatty acids) are common mediators of bacterial behavior, such as chemotaxis and quorum sensing [39–41]. Furthermore, there have been many observed effects of fatty acids on bacterial motility [15, 42–44]. *P. aeruginosa* motility was measured in response to individual polyunsaturated fatty acids by inoculating bacteria into motility plates prepared with M9 minimal media (0.2% glucose, 0.4% casamino acids) and supplemented with 0.4% agar and 300  $\mu$ M of each fatty acid. The soft agar assays revealed significant decreases in motility for all but one fatty acid (20:3) (Fig. 5). Arachidonic and eicosapentaenoic acids elicited a nearly 50% decrease in swimming motility.

### PUFAs influence biofilm formation in *P. aeruginosa*

Formation of biofilms confers advantages to bacteria. The effects of fatty acids on biofilm formation in *P. aeruginosa* was measured using a crystal violet assay, with bacteria grown in the presence of fatty acid for 24 h. The capacity for biofilm formation was tested at physiological pH (7.4) and a lower pH (5.5) to mimic other *P. aeruginosa* infection sites (skin/burn infections). Addition of PUFAs increased biofilm formation in *P. aeruginosa* (Fig. 6). The same phenomenon was further amplified when the assay was performed at a lower pH (5.5).

### Discussion


As microbial resistance strategies emerge, it is important to identify novel ways to target vulnerabilities. It is becoming



**Fig. 3** The effect of exogenous fatty acids on hydrophobic compound uptake in *Pseudomonas aeruginosa*. **a** Bacteria were grown at 37 °C in G56 (pH 7.4) with and without 300 μM of the indicated fatty acids to mid-log phase (OD = 0.8). Cultures were gently pelleted, washed with PBS and resuspended in an equal volume of PBS (OD<sub>600</sub> = 0.4). The amount of CV in the supernatant following centrifugation was measured at regular intervals and expressed graphically as percentage of CV uptake. All standard deviations were less than 3% (not graphed for visual clarity). **b** Bacteria were grown at 37 °C in CM9 with and without 300 μM of the indicated fatty acids to mid-log phase (OD = 0.8). Cultures were gently pelleted, washed with PBS and resuspended in an equal volume of PBS (OD<sub>600</sub> = 0.7). The amount of EtBr in the supernatant following centrifugation was measured as fluorescence emission intensity at 585 nm (excitation wavelength of 530 nm). Asterisks indicate significant difference (\*,  $p < 0.001$ ) as compared to control. **c** Bacteria were grown at 37 °C in CM9 with and without 300 μM of the indicated fatty acids to mid-log phase (OD = 0.8). Cultures were gently pelleted, washed with PBS and resuspended in an equal volume of PBS (OD<sub>600</sub> = 0.4). Following addition of 20 μM EtBr, fluorescence intensity was measured every 5 m for 1 h (excitation wavelength of 550; emission wavelength of 600)

evident that some bacteria have broader capabilities with regard to membrane lipid homeostasis. In addition to altering de novo membrane phospholipid composition in response to environmental stress/stimuli (homeoviscous adaptation), incorporation of exogenous fatty acids constitutes another mechanism by which bacteria capitalize on their surroundings. The current study further defines and expands the fatty acid handling of *P. aeruginosa*, demonstrating structural modifications to phospholipids as well as behavioral changes associated with fatty acid exposure. Considering the pathogenic nature of *P. aeruginosa*, it is tempting to regard fatty acids as important niche-specific nutrients, signaling molecules and/or membrane modifiers. During infection, bacteria encounter free fatty acids [45–48] or liberate fatty acids by enzymatic cleavage of larger lipids. We chose a micromolar concentration (300 μM) to examine the effects of fatty acids on growth. Given the multiple infection sites inhabited by *P. aeruginosa*, the physiological relevance of 300 μM could be dependent upon the site of colonization. We have not verified bacterial responses to other concentrations of exogenous fatty acids.

The current study contributes to recent reports documenting the expanding lipid handling ability of *P. aeruginosa*. Not long after the fatty acid sensor PsrA was discovered [14], multiple FadD acyl CoA synthetase homologs were described in *P. aeruginosa* [26]. More recently, the identification of the PA3286 shunt [49] and ExFadLO [50] illustrate the expanded fatty acid capabilities possessed by *P. aeruginosa*. A bioinformatic survey of several *Pseudomonas* species reveals significant dedication of proteins predicted to be involved in the uptake and assimilation of exogenous fatty acids into phospholipids (Table 1). The conservation of this machinery among pseudomonads may underscore the adaptation to




environments (soil, plant, human) offering a plethora of fatty acids.

Lipid exploitation is achieved by *P. aeruginosa* through key virulence factors delivered via Type III secretion. PopB and PopD mediate membrane lysis following interaction with the eukaryotic lipids cholesterol and phosphatidylserine [51, 52]. ExoU, a phospholipase A2 with affinity for phosphatidylinositol [53, 54], is one of several identified phospholipases that may be involved in chronic pulmonary infection and during pathogenesis of the cystic fibrosis lung [55–62]. In addition, phosphatidylcholine is prevalent in the mammalian lung and is targeted by *P. aeruginosa* during infection [63]. PC species in human lung surfactant contain linoleic and arachidonic acids, fatty acids not synthesized by *P. aeruginosa* [64], yet demonstrated to be incorporated into membrane phospholipids in this study. Other surfactant phospholipids, phosphatidylglycerol and phosphatidylinositol, also contain appreciable amounts of linoleic and arachidonic acid, and these fatty acid constituents are elevated in bronchoalveolar lavage samples from patients with respiratory distress [65]. The principle plasma phospholipid, PC 16:0/18:2, is recognized as a potential marker for uncompromised airways, since infiltration


of this species correlates with severity of the asthmatic response [65]. It is tempting to speculate that host niche availability of phospholipids heightens accessibility to linoleic acid during *P. aeruginosa* infection of the CF lung. Surprisingly, the role of *P. aeruginosa* in the well-established fatty acid abnormalities in CF patients [66, 67] has not been investigated.

Measurement of permeability differed between crystal violet and ethidium bromide. Since crystal violet can bind to bacterial surfaces, the ethidium bromide assays constitute a better assessment of permeability caused by the PUFAs. We tested the accessibility of ethidium bromide by measuring both exclusion and accumulation of ethidium bromide. Both assays revealed similar trends, with dihomo-gamma-linolenic acid (20:3) eliciting the least membrane permeability. Interestingly, with the exception of 20:3, the accumulation assay correlated carbon number with permeability, with the 20-carbon PUFAs (arachidonic, eicosapentaenoic, and docosahexaenoic acids) causing elevated accumulation as compared to the 18-carbon PUFAs. Membrane permeability was not predictive of antimicrobial peptide resistance or biofilm formation, but it is intriguing to note that the observed decreases in



motility correspond with permeability. Specifically, 20:3 exhibits little change whereas 20:4 and 20:5 exhibit significant changes compared to the control.

The effect of fatty acids on polymyxin B and colistin sensitivity are noteworthy. The results demonstrate that availability of several fatty acids raises the minimum inhibitory concentration of the cyclic peptide antibiotics tested, which are similar to cationic antimicrobial peptides (AMPs). These innate immune effectors were chosen because their activity is thought to rely upon intercalation in the membrane bilayer to eventually cause cell lysis [68]. Accordingly, assimilation of exogenous PUFAs into membrane phospholipids was hypothesized to alter AMP resistance. The most significant effects were observed with arachidonic acid, a prevalent fatty acid in eukaryotic phospholipids and



mediator of cellular signaling and inflammation [69]. Rajamoorthi et al. [70] used deuterium NMR spectroscopy and small angle X-ray diffraction of n-6 (20:4) and n-3 (22:6) phospholipid bilayers to demonstrate distinct properties between the bilayers. Although both fatty acids confer membrane relaxation and reduced bilayer thickness, the n-6 (20:4)-containing bilayer exhibited a more disordered and deformable bilayer than the n-3 (22:6) bilayer [65]. Thus, contrary to our findings, it would be expected that incorporation of arachidonic acid might make the bacterial membranes more vulnerable to attack by AMPs. Another consideration for phospholipid alterations involves bacterial maintenance of membrane lipids with enzymes that change the fatty acids stereochemistry, such as cis/trans isomerase, a predicted periplasmic enzyme encoded by many *Pseudomonas* genomes [71]. Adoption of the *trans* conformation could explain both decreased permeability and heightened resistance to PMB and colistin observed in the current

**Table 1** *Pseudomonas aeruginosa* possesses an expanded repertoire of genes involved in fatty acid uptake

	FadL	FadD	PlsB/PlsC	PlsX/PlsY
<i>P. aeruginosa</i> PAO1	PA1288 PA1764, PA4589	PA3300, PA3299, PA3924, PA4198, PA2557, PA1617, PA3860,	PA3673 /PA3267, PA0358	PA2969 /PA0581
<i>P. putida</i> S12	RPPX_15880, RPPX_25840	RPPX_02635, RPPX_02630, RPPX_05335, RPPX_23090, RPPX_00575, RPPX_21065	RPPX_15320 /RPPX_16685, RPPX_09090	RPPX_17030 /RPPX_07310
<i>P. fluorescens</i> F113	PSF113_4386	PSF113_1301, PSF113_1302, PSF113_3051, PSF113_3081, PSF113_3882, PSF113_0964	PSF113_1116/PSF113_4376	PSF113_4149/ PSF113_5367
<i>P. syringae</i> B728a	Psyr_3669	Psyr_3836, Psyr_3834, Psyr_0990	Psyr_1328 / Psyr_1586, Psyr_0009	Psyr_1645 / Psyr_4637

*Pseudomonas aeruginosa* was bioinformatically assessed for homologs to FadL, FadD and acyltransferases involved in utilization of exogenous fatty acids. The identified homologues illustrate the enhanced ability for *Pseudomonas* species to acquire and utilize exogenous fatty acids



study. Furthermore, antibiotic attack relying on another mechanism (imipenem) did not significantly alter resistance. Utilization of another minimal medium (CM9) for polymyxin B yielded similar patterns although a 4-fold increase in resistance was observed with docosahexaenoic acid (22:6). Ongoing studies are defining the stereochemistry of phospholipids extracted from fatty acid exposed *P. aeruginosa*.

The link between pathogenicity and motility has been established for several pseudomonads, including *P. fluorescens* [72], *P. syringae* [73] and *P. aeruginosa* [74]. It is unknown whether PUFAs are chemotactic signaling molecules for *P. aeruginosa*, but the genomic possession of multiple gene clusters dedicated to chemotaxis suggests a wider repertoire of sensory capabilities [75]. Our findings of decreased motility in response to each PUFA may have ramifications for *P. aeruginosa* infection. Recently, swimming motility of *P. aeruginosa* was found to be instrumental in the formation of neutrophil extracellular traps, an important immune strategy to fight early infection [76]. A decrease in swimming motility in response to host fatty acids may contribute to early pathogenesis of *P. aeruginosa*. The fatty acid-mediated effects on swarming and twitching motility are under investigation. Importantly, we have not observed significant growth defects associated with fatty acids supplemented at a concentration of 300  $\mu$ M (data not shown).

Biofilms contribute to the persistence of *P. aeruginosa* infection, and the impact of PUFAs on their formation has not been reported. The increase in biofilm production of the control culture from pH 5.5 to 7.4 correlates to previous studies of biofilm formation and pH in *P. aeruginosa* [77]; thus, our results suggest that exogenous PUFA availability may enable elevated biofilm formation in acidic conditions. *P. aeruginosa* biofilm cultures have been shown to contain a higher degree of long chain unsaturated fatty acids, but lower overall carbon length, as compared to planktonic cultures [78]. It is unknown whether, or to what extent, the exogenous fatty acids are assimilated in the biofilm cultures, as this was not analyzed in the current study. Further research is necessary to explore the connection between pH, biofilm formation and exogenous fatty acid utilization.

The hijacking of arachidonic acid from sites of infection could be advantageous for *P. aeruginosa* colonization and persistence. Assimilation of available PUFAs during infection may not only strengthen bacterial membranes, but also misguide the cellular responses reliant upon fatty acid signaling pathways. For example, the availability of unsaturated fatty acids increases macrophage phagocytosis of *P. aeruginosa* [79]. The anti-inflammatory and immunomodulatory effects of long chain polyunsaturated fatty acids have been documented [30, 32]. The administration of fatty acids during experimental and clinical *P. aeruginosa*

infection has produced mixed results. While experimental studies have observed decreased mortality, decreased bacterial load and an anti-inflammatory immune response in mice [80], the human response is inconclusive. There is some precedent for the therapeutic potential of PUFAs. In two studies, the administration of n-6 PUFAs enhanced antibiotic activity against *P. aeruginosa* [81, 82]. Our results suggest that *P. aeruginosa* can achieve increased resistance to antimicrobial peptides when physiologically relevant exogenous fatty acids are available.

## Conclusions

Collectively, our findings emphasize the role that fatty acids may play in bacterial physiology, particularly for pathogens with the ability to utilize fatty acids for enhanced virulence and survival. The data herein demonstrate incorporation of several PUFAs into the phospholipids of *P. aeruginosa*. The exogenous PUFAs also affected membrane permeability, swimming motility and biofilm formation. Importantly, the presence of certain PUFAs increased the MICs of polymyxin B and colistin, suggesting a potential role of fatty acids in the pathogenesis of *P. aeruginosa* infections.

## Additional files

**Additional file 1: Figure S1.** Growth pattern of *Pseudomonas aeruginosa* in minimal media supplemented with individual fatty acids. Cultures of *Pseudomonas aeruginosa* were grown with or without 300  $\mu$ M of the indicated fatty acids at 37 °C in G56 (pH 7.4) for 12 h. Cultures were inoculated at a starting OD<sub>600</sub> of 0.05 and growth was assessed by measuring the absorbance (OD<sub>600</sub>) of the cultures every 40 min. (TIF 7504 kb)

**Additional file 2: Figure S2.** Growth pattern of *Pseudomonas aeruginosa* in the presence of exogenous fatty acids as the sole carbon source. Exogenous fatty acids (1 mM) were supplied in M9 minimal media (starting OD = 0.05; no glucose) as the sole carbon source and growth was monitored for 12 h at 37 °C. A positive control was included supplemented with 0.2% glucose. (TIF 9385 kb)

**Additional file 3: Figure S3.** Ultra performance liquid chromatography-mass spectrometry of isolated phospholipids from *Pseudomonas aeruginosa* grown in the presence and absence of fatty acids. Comparison of other fatty acids tested not shown in Fig. 2a (main text). All fatty acids tested showed altered chromatograms compared to the control. (TIF 3760 kb)

**Additional file 4: Figure S4.** Mass spectrometry of individual phospholipids from *Pseudomonas aeruginosa* grown in the presence and absence of fatty acids. Mass spectra for each of the peaks shown in Fig. 2b. The parent *m/z* is indicated and this is the value that was searched in the LIPID MAPS database. Identity of the specific phospholipid is indicated. Note that RT = retention time corresponding to the XIC in Fig. 2b. (TIF 21199 kb)

## Abbreviations

AMP: Antimicrobial peptide; CL: Cardiolin (diphosphatidylglycerol); PE: Phosphatidylethanolamine; PG: Phosphatidylglycerol; PUFA: Polyunsaturated fatty acid

## Acknowledgements

Portions of this study have been previously presented at the 75th annual meeting of the Association of Southeastern Biologists. Specifically, the abstract (first two sentences) contains text borrowed from the abstract used for the conference. (<https://ia800605.us.archive.org/32/items/southeasternbio61assob/southeasternbio61assob.pdf>).

**Funding**

The work was made possible by internal funding awards to LYB, WCB, MSG and DKG. The funding source had no role in the design of the study and collection, analysis, and interpretation of data.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article [and its supplementary information files].

**Authors' contributions**

LYB, DKG, and SJS were major contributors in writing the manuscript. LYB and DKG performed, analyzed and interpreted the thin-layer chromatography. DKG performed, analyzed and interpreted the ethidium bromide assays, imipenem assays and bioinformatics. LYB performed, analyzed and interpreted the antimicrobial peptide assays. CRH performed the growth curve and motility assays. AWS, WCB and MSG performed, analyzed and interpreted the biofilm and crystal violet uptake assays. DMA and SJS performed, analyzed and interpreted the UPLC/MS data. All authors have read and approved this manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

<sup>1</sup>Department of Biology, Geology, and Environmental Science, The University of Tennessee at Chattanooga, Chattanooga, TN, USA. <sup>2</sup>Department of Chemistry and Physics, The University of Tennessee at Chattanooga, Chattanooga, TN, USA.

Received: 17 January 2018 Accepted: 5 September 2018

Published online: 14 September 2018

**References**

- Oberhardt MA, Puchalka J, Fryer KE, Martins dos Santos VAP, Papin JA. Genome-scale metabolic network analysis of the opportunistic pathogen *Pseudomonas aeruginosa* PAO1. *J Bacteriol*. 2008;190:2790–803.
- Balasubramanian D, Schneper L, Kumari H, Mathee K. A dynamic and intricate regulatory network determines *Pseudomonas aeruginosa* virulence. *Nucleic Acids Res*. 2012;41:1–20.
- Williams P, Cámara M. Quorum sensing and environmental adaptation in *Pseudomonas aeruginosa*: a tale of regulatory networks and multifunctional signal molecules. *Curr Opin Microbiol*. 2009;12:182–91.
- Liu YC, Chan KG, Chang CY. Modulation of host biology by *Pseudomonas aeruginosa* quorum sensing signal molecules: messengers or traitors. *Front Microbiol*. 2015; <https://doi.org/10.3389/fmicb.2015.01226>. eCollection 2015.
- Jimenez PN, Koch G, Thompson JA, Xavier KB, Cool RH, Quax WJ. The multiple signaling systems regulating virulence in *Pseudomonas aeruginosa*. *Microbiol Mol Biol Rev*. 2012;76:46–65.
- Fozo EM, Rucks EA. The role of bacterial lipid synthesis and the harnessing of host lipids in bacterial pathogenesis. *Adv Microb Physiol*. 2016;69:51–155.
- Ramaswamy AV, Maurelli AT. *Chlamydia trachomatis* serovar L2 can utilize exogenous lipoic acid through the action of the lipoic acid ligase LplA1. *J Bacteriol*. 2010;192:6172–81.
- Pride AC, Herrera CM, Guan Z, Giles DK, Trent MS. The outer surface lipoprotein VolA mediates utilization of exogenous lipids by *Vibrio cholerae*. *MBio*. 2013;4(3):e00305–13. <https://doi.org/10.1128/mBio.00305-13>.
- Wier AM, Nyholm SV, Mandel MJ, Massengo-Tiassé RP, Schaefer AL, Koroleva I, et al. Transcriptional patterns in both host and bacterium underlie a daily rhythm of anatomical and metabolic change in a beneficial symbiosis. *Proc Natl Acad Sci U S A*. 2010;107:2259–64.
- Giles DK, Hankins JV, Guan Z, Trent MS. Remodelling of the *Vibrio cholerae* membrane by incorporation of exogenous fatty acids from host and aquatic environments. *Mol Microbiol*. 2011;79:716–28.
- Moravec AR, Siv AW, Hobby CR, Lindsay EN, Norbush LV, Shults DJ, et al. Exogenous polyunsaturated fatty acids (PUFAs) impact membrane remodeling and affect virulence phenotypes among pathogenic *Vibrio* species. *Appl Environ Microbiol*. 2017;83:e01415–7.
- Eder AE, Munir SA, Hobby CR, Anderson DM, Herndon JL, Siv AW, et al. Exogenous polyunsaturated fatty acids (PUFAs) alter phospholipid composition, membrane permeability, biofilm formation and motility in *Acinetobacter baumannii*. *Microbiology*. 2017;163:1626–36.
- Hobby CR, Herndon JL, Morrow CA, Peters RE, Symes SJK, Giles DK. Exogenous fatty acids alter phospholipid composition, membrane permeability, capacity for biofilm formation, and antimicrobial peptide susceptibility in *Klebsiella pneumoniae*. *MicrobiologyOpen*. 2018;e00635. <https://doi.org/10.1002/mbio.3635>
- Kang Y, Nguyen DT, Son MS, Hoang TT. The *Pseudomonas aeruginosa* PsrA responds to long-chain fatty acid signals to regulate the fadBA5 beta-oxidation operon. *Microbiology*. 2008;154:584–98.
- Liaw SJ, Lai HC, Wang WB. Modulation of swarming and virulence by fatty acids through the RsbA protein in *Proteus mirabilis*. *Infect Immun*. 2004;72:6836–45.
- Kenny JG, Ward D, Josefsson E, Johnsson IM, Hinds J, Rees HH, et al. The *Staphylococcus aureus* response to unsaturated long chain free fatty acids: survival mechanisms and virulence implications. *PLoS One*. 2009; <https://doi.org/10.1371/journal.pone.0004344>.
- Sun Y, Wilkinson BJ, Standiford TJ, Akinbi HT, O'Riordan MXD. Fatty acids regulate stress resistance and virulence factor production for *Listeria monocytogenes*. *J Bacteriol*. 2012;194:5274–84.
- Sheu CW, Freese E. Effects of fatty acids on growth and envelope proteins of *Bacillus subtilis*. *J Bacteriol*. 1972;111:516–24.
- Thompson L, Cockayne A, Spiller RC. Inhibitory effect of polyunsaturated fatty acids on the growth of *Helicobacter pylori*: a possible explanation of the effect of diet on peptic ulceration. *Gut*. 1994;35:1557–61.
- Giamarellos-Bourboulis EJ, Grecka P, Dionysiou-Asteriou A, Giamarellou H. *In vitro* influence of polyunsaturated fatty acids on nosocomial *Pseudomonas aeruginosa*: a preliminary report. *Int J Antimicrob Agents*. 1995;6:47–50.
- Miller RD, Brown KE, Morse SA. Inhibitory action of fatty acids on the growth of *Neisseria gonorrhoeae*. *Infect Immun*. 1977;17:303–12.
- Ginsburgh CL, Black PN, Nunn WD. Transport of long chain fatty acids in *Escherichia coli*. Identification of a membrane protein associated with the fadL gene. *J Biol Chem*. 1984;259:8437–43.
- Black PN, DiRusso CC. Transmembrane movement of exogenous long-chain fatty acids: proteins, enzymes, and vectorial esterification. *Microbiol Mol Biol Rev*. 2003;67:454–72.
- Zhang Y-M, Rock CO. Acyltransferases in bacterial glycerophospholipid synthesis. *J Lipid Res*. 2008;37:911–7.
- García B, Olivera ER, Miñambres B, Fernández-Valverde M, Cañedo LM, Prieto MA, et al. Novel biodegradable aromatic plastics from a bacterial source. Genetic and biochemical studies on a route of the phenylacetyl-coa catabolon. *J Biol Chem*. 1999;274:29228–41.
- Kang Y, Zarzycki-Siek J, Walton CB, Norris MH, Hoang TT. Multiple FadD acyl-CoA synthetase contribute to differential fatty acid degradation and virulence in *Pseudomonas aeruginosa*. *PLoS One*. 2010; <https://doi.org/10.1371/journal.pone.0013557>.
- Kang Y, Lunin WV, Skarina T, Savchenko A, Schurr MJ, Hoang TT. The long-chain fatty acid sensor, PsrA, modulates the expression of *rpoS* and the type III secretion exsCEBA operon in *Pseudomonas aeruginosa*. *Mol Microbiol*. 2009;73:120–36.
- Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE. Essential fatty acids in visual and brain development. *Lipids*. 2001;36:885–95.
- Abedi E, Sahari MA. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. *Food Sci Nutr*. 2014; 2:443–63.
- Valentine RC, Valentine DL. Omega-3 fatty acids in cellular membranes: a unified concept. *Prog Lipid Res*. 2004;43:383–402.
- Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. *Prog Lipid Res*. 2014;53:124–44.
- Siriwardhana N, Kalupahana NS, Fletcher S, Xin W, Claycombe KJ, Quignard-Boulange A, et al. n-3 and n-6 polyunsaturated fatty acids differentially

- regulate adipose angiotensinogen and other inflammatory adipokines in part via NF- $\kappa$ B-dependent mechanisms. *J Nutr Biochem*. 2012;23:1661–7.
33. Pierre M, Husson MO, Le Berre R, Desseyn JL, Galabert C, Beghin L, et al. Omega-3 polyunsaturated fatty acids improve host response in chronic *Pseudomonas aeruginosa* lung infection in mice. *Am J Physiol Lung Cell Mol Physiol*. 2007;292:1422–31.
  34. Tetaert D, Pierre M, Demeyer D, Husson MO, Beghin L, Galabert C, et al. Dietary n-3 fatty acids have suppressive effects on mucin upregulation in mice infection with *Pseudomonas aeruginosa*. *Respir Res*. 2007;8:39.
  35. Tiesset H, Pierre M, Desseyn JL, Guery B, Beermann C, Galabert C, et al. Dietary (n-3) polyunsaturated fatty acids affect the kinetics of pro- and anti-inflammatory responses in mice with *Pseudomonas aeruginosa* lung infection. *J Nutr*. 2009;139:82–9.
  36. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, et al. Comprehensive transposon mutant library of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A*. 2003;100:14339–44.
  37. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol*. 1957;37:911–7.
  38. O'Toole G. Microtiter dish biofilm formation assay. *J Vis Exp*. 2011; <https://doi.org/10.3791/2437>.
  39. Miller RM, Tomaras AP, Barker AP, Voelker DR, Chan ED, Vasil AI, et al. *Pseudomonas aeruginosa* twitching motility-mediated chemotaxis towards phospholipids and fatty acids: specificity and metabolic requirements. *J Bacteriol*. 2008;190:4038–49.
  40. Neitzel JJ. Fatty acid molecules: a role in cell signaling. *Nat Educ*. 2010;3:57.
  41. Nikolakakis K, Monfils K, Moriano-Guitierrez S, Brennan CA, Ruby EG. Characterization of the *Vibrio fischeri* fatty acid chemoreceptors, VfcB and VfcB2. *Appl Environ Microbiol*. 2015;82:696–704.
  42. Chatterjee A, Dutta PK, Chowdhury R. Effect of fatty acids and cholesterol present in bile on expression of virulence factors and motility of *Vibrio cholerae*. *Infect Immun*. 2007;75:1946–53.
  43. Tobe T, Nakanishi N, Sugimoto N. Activation of motility by sensing short-chain fatty acids via two steps in a flagellar gene regulatory cascade in enterohemorrhagic *Escherichia coli*. *Infect Immun*. 2011;79:1016–24.
  44. Lai HC, Soo PC, Wei JR, Yi WC, Liaw SJ, Horng YT, et al. The RssAB two-component signal transduction system in *Serratia marcescens* regulates swarming motility and cell envelope architecture in response to exogenous saturated fatty acids. *J Bacteriol*. 2005;187:3407–14.
  45. Farrell PM, Mischler EH, Engle MJ, Brown J, Lau S-M. Fatty acid abnormalities in cystic fibrosis. *Pediatric Res*. 1985;19:104–9.
  46. Patil VS, Magar NG. Fatty acids of human blood. *Biochem J*. 1960;74:427–9.
  47. Kim KM, Jung BH, Lho DS, Chung WY, Paeng KJ, Chung BC. Alteration of urinary profiles of endogenous steroids and polyunsaturated fatty acids in thyroid cancer. *Cancer Lett*. 2003;202:173–9.
  48. Wang P, Sun M, Ren J, Djuric Z, Fisher GJ, Wang X, et al. Gas chromatography-mass spectrometry analysis of effects of dietary fish oil on total fatty acid composition in mouse skin. *Sci Rep*. 2014; <https://doi.org/10.1038/srep42641>.
  49. Yuan Y, Leeds JA, Meredith TC. *Pseudomonas aeruginosa* directly shunts  $\beta$ -oxidation degradation intermediates into *de novo* fatty acid biosynthesis. *J Bacteriol*. 2012;194:5185–96.
  50. Martinez E, Estupinan M, Javier Pastor FI, Busquets M, Diaz P, Manresa A. Functional characterization of ExFadLO, an outer membrane protein required for exporting oxygenated long-chain fatty acids in *Pseudomonas aeruginosa*. *Biochimie*. 2013;95:290–8.
  51. Schoehn G, Di Guilmi AM, Lemaire D, Attree I, Weissenhorn W, Dessen A. Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in *Pseudomonas*. *EMBO J*. 2003;22:4957–67.
  52. Faudry E, Vernier G, Neumann E, Forge V, Attree I. Synergistic pore formation by type III toxin translocators of *Pseudomonas aeruginosa*. *Biochemistry*. 2006;45:8117–23.
  53. Tyson GH, Hauser AR. Phosphatidylinositol 4,5-bisphosphate is a novel coactivator of the *Pseudomonas aeruginosa* cytotoxin ExoU. *Infect Immun*. 2013;81:2873–81.
  54. Sato H, Frank DW. Intoxication of host cells by the T3SS phospholipase ExoU: PI(4,5)P<sub>2</sub>-associated, cytoskeletal collapse and late phase membrane blebbing. *PLoS One*. 2014; <https://doi.org/10.1371/journal.pone.0103127>.
  55. Schuler GS, Feltman H, Rabin SDP, Martin CG, Battle SE, Rello J, et al. Secretion of the toxin ExoU is a marker for highly virulent *Pseudomonas aeruginosa* isolates obtained from patients with hospital-acquired pneumonia. *J Infect Dis*. 2003;188:1695–706.
  56. Wilderman PJ, Vasil AI, Johnson Z, Vasil ML. Genetic and biochemical analyses of a eukaryotic-like phospholipase D of *Pseudomonas aeruginosa* suggest horizontal acquisition and a role for persistence in a chronic pulmonary infection model. *Mol Microbiol*. 2001;39:291–303.
  57. Wieland CW, Siegmund B, Senaldi G, Vasil ML, Dinarello CA, Fantuzzi G. Pulmonary inflammation induced by *Pseudomonas aeruginosa* lipopolysaccharide, phospholipase C, and exotoxin a: role of interferon regulatory factor 1. *Infect Immun*. 2002;70:1352–8.
  58. Wargo MJ, Gross MJ, Rajamani S, Allard JL, Lundblad LK, Allen GB, et al. Hemolytic phospholipase C inhibition protects lung function during *Pseudomonas aeruginosa* infection. *Am J Resp Crit Care Med*. 2011;184:345–54.
  59. Lopez DJ, Collado MI, Ibguren M, Vasil AI, Vasil ML, Goni FM, et al. Multiple phospholipid substrates of phospholipase C/sphingomyelinase HR<sub>2</sub> from *Pseudomonas aeruginosa*. *Chem Phys Lipids*. 2011;164:78–82.
  60. Agassandian M, Miakotina OL, Andrews M, Mathur SN, Mallampalli RK. *Pseudomonas aeruginosa* and sPLA<sub>2</sub> IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPAR $\alpha$ -RXR. *Biochem J*. 2007;403:409–20.
  61. Spencer C, Brown HA. Biochemical characterization of a *Pseudomonas aeruginosa* phospholipase D. *Biochemistry*. 2015;54:1208–18.
  62. da Mata Madeira PV, Zouhir S, Basso P, Neves D, Laubier A, Salacha R, et al. Structural basis of lipid targeting and destruction by the type V secretion system of *Pseudomonas aeruginosa*. *J Mol Biol*. 2016;428:1790–803.
  63. Sun Z, Kang Y, Norris MH, Troyer RM, Son MS, Schweizer HP, et al. Blocking phosphatidylcholine utilization in *Pseudomonas aeruginosa*, via mutagenesis of fatty acid, glycerol and choline degradation pathways, confirms the importance of this nutrient source *in vivo*. *PLoS One*. 2014; <https://doi.org/10.1371/journal.pone.0103778>.
  64. Schmidt R, Meier U, Yabut-Perez M, Walrath D, Grimminger F, Seeger W, et al. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. *Am J Respir Crit Care Med*. 2001;163:95–100.
  65. Heeley EL, Hohfeld JM, Postle AD. Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma. *Am J Physiol Lung Cell Mol Physiol*. 2000;278:L305–11.
  66. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. *N Engl J Med*. 2004;350:560–9.
  67. Seegmiller AC. Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications. *Int J Mol Sci*. 2014;15:16083–99.
  68. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol*. 2005;3:238–50.
  69. Zurier RB. Fatty acids, inflammation and immune responses. *Prostaglandins Leukot Essent Fatty Acids*. 1993;48:57–62.
  70. Rajamoorthi K, Petrache HI, McIntosh TJ, Brown MF. Packing and viscoelasticity of polyunsaturated omega-3 and omega-6 lipid bilayers as seen by (2)H NMR and X-ray diffraction. *J Am Chem Soc*. 2005;127:1576–88.
  71. Heipieper JH, Meinhardt F, Segura A. The cis-trans isomerase of unsaturated fatty acids in *Pseudomonas* and *Vibrio*: biochemistry, molecular biology and physiological function of a unique stress adaptive mechanism. *FEMS Microbiol Lett*. 2003;229:1–7.
  72. De Weger LA, van der Vlugt CI, Wijffes AH, Bakker PA, Schippers B, Lugtenberg B. Flagella of a plant-growth-stimulating *Pseudomonas fluorescens* strain are required for colonization of potato roots. *J Bacteriol*. 1987;169:2769–73.
  73. Manoharan B, Neale HC, Hancock JT, Jackson RW, Arnold DL. The identification of genes important in *Pseudomonas syringae* pv. Phaseolicola plant colonization using in vitro screening of transposon libraries. *PLoS One*. 2015; <https://doi.org/10.1371/journal.pone.0137355>.
  74. Kazmierczak BI, Sniederberend M, Jain R. Cross-regulation of *Pseudomonas* motility systems: the intimate relationship between flagella, pili and virulence. *Curr Opin Microbiol*. 2015;28:78–82.
  75. Kato J, Kim HE, Takiguchi N, Kuroda A, Ohtake H. *Pseudomonas aeruginosa* as a model organism for investigation of chemotactic behaviors in ecosystem. *J Biosci Bioeng*. 2008;106:1–7.
  76. Floyd M, Winn M, Cullen C, Sil P, Chassaing B, Yoo DG, et al. Swimming motility mediates the formation of neutrophil extracellular traps induced by flagellated *Pseudomonas aeruginosa*. *PLoS Pathog*. 2016; <https://doi.org/10.1371/journal.ppat.1005987>.

77. Hostacká A, Ciznár I, Stefkovicová M. Temperature and pH affect the production of bacterial biofilm. *Folia Microbiol.* 2010;55:75–8.
78. Chao J, Wolfaardt GM, Arts MT. Characterization of *Pseudomonas aeruginosa* fatty acid profiles in biofilms and batch planktonic cultures. *Can J Microbiol.* 2010;56:1028–39.
79. Adolph S, Fuhrmann H, Schumann J. Unsaturated fatty acids promote the phagocytosis of *P. aeruginosa* and *R. equi* by RAW264.7 macrophages. *Curr Microbiol.* 2012;65:649–55.
80. Caron E, Desseyn JL, Sergent L, Bartke N, Husson MO, Duhamel A, et al. Impact of fish oils on the outcomes of a mouse model of acute *Pseudomonas aeruginosa* pulmonary infection. *Br J Nutr.* 2015;113:191–9.
81. Giamarellos-Bourboulis EJ, Grecka P, Dionyssiou-Asteriou A, Giamarellou H. *In vitro* activity of polyunsaturated fatty acids on *Pseudomonas aeruginosa*: relationship to lipid peroxidation. *Prostaglandin Leukot Essent Fatty Acids.* 1998;72:357–62.
82. Giamarellos-Bourboulis EJ, Mouktaroudi M, Adamis T, Kousoulas V, Baziaka F, Perrea D, et al. N-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2004;48:4713–7.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

